Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS)

Journal of Adolescent Health

Volumn 29, Issue 3, 2001, Pages 160-169

  Glueck, C J ^a,b   Wang, Ping ^a   Fontaine, Robert ^a   Tracy, Trent ^a   Sieve Smith, Luann ^a  

^a JEWISH HOSPITAL   (United States)

^b Cholesterol Center   (United States)

Author keywords

Adolescents; Insulin resistance; Menstrual cycles; Metformin; Oligo amenorrhea; Polycystic ovary syndrome

Indexed keywords

CARBOHYDRATE; CHOLESTEROL; ESTRADIOL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PROGESTERONE; TESTOSTERONE;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; EXPERIENCE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; NAUSEA; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN DIET;

ADOLESCENT; AMENORRHEA; BLOOD GLUCOSE; CASE-CONTROL STUDIES; COHORT STUDIES; DIETARY CARBOHYDRATES; DIETARY PROTEINS; FEMALE; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MENSTRUATION; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 0034880066     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-139X(01)00202-6     Document Type: Article

References (35)

1. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome
2. Plasminogen activator inhibitor activity; An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome
3. Effects of Metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
4. Decrease in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome
5. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
6. Menstrual cyclicity after Metformin therapy in polycystic ovary syndrome
7. Metformin therapy is associated with decreased plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with polycystic ovary syndrome
8. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
9. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome
10. Endocrine features of polycystic ovary syndrome in a random population sample of 14-16 year old adolescents
11. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment
12. Menstrual disorders in adolescents; Excess androgens and the polycystic ovary syndrome
13. Polycystic ovary syndrome
14. Hormonal effects of flutamide in young women with polycystic ovary syndrome
15. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome; A randomized double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
16. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity
17. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovarian syndrome
18. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
19. Clinical assessment of body hair growth in women
20. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy
21. Polycystic ovary syndrome; A changing perspective
22. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis
23. Endometrial carcinoma. Ovarian-dysfunction-a risk factor in young women
24. Can metformin reduce insulin resistance in polycystic ovary syndrome?
25. Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome
26. Hepatotoxicity due to troglitazone; Report of two cases and review of adverse events reported to the United States Food and Drug Administration
27. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension, and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome
28. Cardiovascular consequences of polycystic ovary syndrome
29. Contribution of fasting hyperinsulinemia to prediction of atherosclerotic disease status in 293 hyperlipidemic patients
30. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization
31. Insulin sensitizing agents and polycystic ovary syndrome
32. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women
33. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome